Melvin J. Yu
About
In The Last Decade
Melvin J. Yu
30 papers receiving 1.1k citations
Peers
Comparison fields: 5 of 93
- Oncology 422
- Molecular Biology 402
- Organic Chemistry 326
- Pharmacology 205
- Biotechnology 141
Countries citing papers authored by Melvin J. Yu
This map shows the geographic impact of Melvin J. Yu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Melvin J. Yu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Melvin J. Yu more than expected).
Fields of papers citing papers by Melvin J. Yu
This network shows the impact of papers produced by Melvin J. Yu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Melvin J. Yu. The network helps show where Melvin J. Yu may publish in the future.
Co-authorship network of co-authors of Melvin J. Yu
This figure shows the co-authorship network connecting the top 25 collaborators of Melvin J. Yu. A scholar is included among the top collaborators of Melvin J. Yu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Melvin J. Yu. Melvin J. Yu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 86 | |
| 2 | 11 | |
| 3 | Broad spectrum preclinical antitumor activity of eribulin (Halaven(R)): optimal effectiveness under intermittent dosing conditions. | 38 |
| 4 | 5 | |
| 5 | 5 | |
| 6 | 12 | |
| 7 | 16 | |
| 8 | 16 | |
| 9 | 27 | |
| 10 | 111 | |
| 11 | Antiproliferative effects of halichondrin B analog eribulin mesylate (E7389) against paclitaxel-resistant human cancer cells in vitro | 40 |
| 12 | 56 | |
| 13 | 41 | |
| 14 | 7 | |
| 15 | 18 | |
| 16 | 30 | |
| 17 | 37 | |
| 18 | 55 | |
| 19 | 3 | |
| 20 | 20 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.